[go: up one dir, main page]

WO2004044155A3 - MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE - Google Patents

MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE Download PDF

Info

Publication number
WO2004044155A3
WO2004044155A3 PCT/US2003/035693 US0335693W WO2004044155A3 WO 2004044155 A3 WO2004044155 A3 WO 2004044155A3 US 0335693 W US0335693 W US 0335693W WO 2004044155 A3 WO2004044155 A3 WO 2004044155A3
Authority
WO
WIPO (PCT)
Prior art keywords
mip
csf
adjuvants
vaccine
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/035693
Other languages
French (fr)
Other versions
WO2004044155A2 (en
WO2004044155A8 (en
Inventor
Paul Mckay
Dan Barouch
Norman Letvin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Priority to AU2003291402A priority Critical patent/AU2003291402A1/en
Publication of WO2004044155A2 publication Critical patent/WO2004044155A2/en
Publication of WO2004044155A8 publication Critical patent/WO2004044155A8/en
Anticipated expiration legal-status Critical
Publication of WO2004044155A3 publication Critical patent/WO2004044155A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention features methods to substantially increase the immunogenicity of a vaccine, preferably a DNA vaccine, and involves providing a mammal with a vaccine regimen, which include at least one immunogen, GM-CSF, and MIP- I α in the absence of exogenous IL-4. The methods of the present invention are useful for the prevention, treatment, and reduction of various pathological states, including for example, cancer, microbial infections, autoimmune diseases, tissue rejection, and allergic reactions.
PCT/US2003/035693 2002-11-07 2003-11-07 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE Ceased WO2004044155A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003291402A AU2003291402A1 (en) 2002-11-07 2003-11-07 MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42465802P 2002-11-07 2002-11-07
US60/424,658 2002-11-07

Publications (3)

Publication Number Publication Date
WO2004044155A2 WO2004044155A2 (en) 2004-05-27
WO2004044155A8 WO2004044155A8 (en) 2004-08-19
WO2004044155A3 true WO2004044155A3 (en) 2005-10-06

Family

ID=32312848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035693 Ceased WO2004044155A2 (en) 2002-11-07 2003-11-07 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Country Status (2)

Country Link
AU (1) AU2003291402A1 (en)
WO (1) WO2004044155A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070099013A (en) * 2005-01-31 2007-10-08 주식회사 에펙타 세포연구소 Immune enhancers
WO2009024426A1 (en) * 2007-07-27 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunizing compositions for inducing 'bystander' killing of pathogens
SMT202000101T1 (en) 2008-10-10 2020-03-13 Childrens Medical Center Biochemically stabilized hiv-1 env trimer vaccine
WO2012023631A1 (en) * 2010-08-19 2012-02-23 株式会社Eci Pharmaceutical composition for inhibiting proliferation of cancer cells which comprises heat shock protein (hsp) and eci301 polypeptide, and cancer treatment method using same
CN105263506B (en) 2013-01-07 2018-03-09 贝丝以色列女执事医疗中心 Stable human immunodeficiency virus (HIV) coating (EnV) tripolymer vaccine and its application method
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
EP3052518B1 (en) 2013-10-04 2020-01-08 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
CA2961024A1 (en) 2014-09-26 2016-03-31 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
CA3008542C (en) 2015-12-15 2020-06-02 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
JP6595132B2 (en) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー HIV vaccine preparation
CN110494159A (en) 2016-09-02 2019-11-22 扬森疫苗与预防公司 Method of the induction for the immune response of HIV infection in the object of antiretroviral therapy
SG10202001956UA (en) 2016-09-15 2020-04-29 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
EP3638302B1 (en) 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
MY200554A (en) 2017-07-19 2024-01-03 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US12459989B2 (en) 2018-11-21 2025-11-04 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
US20240197867A1 (en) * 2021-02-26 2024-06-20 The Feinstein Institutes For Medical Research Neural control of adaptive immunity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation

Also Published As

Publication number Publication date
WO2004044155A2 (en) 2004-05-27
AU2003291402A8 (en) 2004-06-03
AU2003291402A1 (en) 2004-06-03
WO2004044155A8 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2004044155A8 (en) MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2005052119A3 (en) Adjuvants of immune response
WO2009135199A3 (en) Vaccine compositions and methods
WO2004084936A3 (en) Modified free-living microbes, vaccine compositions and methods of use thereof
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
WO2005009463A3 (en) Antigen-presenting cell vaccines and methods of use thereof
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
NO20015073D0 (en) vaccinations
WO2001082963A3 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
BR0316758A (en) Yeast-based vaccines as immunotherapy
EP2433954A3 (en) Identification of tumor-associated antigens for diagnosis and therapy
AU2002338832A1 (en) Vaccine
WO2007006712A3 (en) Mycoplasma subunit vaccine
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
WO2003090687A3 (en) Using heat shock proteins to increase immune response
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2006113622A3 (en) Direct vaccination of the bone marrow
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
MY127452A (en) Vaccines.
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
WO2007008904A3 (en) Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
WO2003057823A3 (en) Epitope synchronization in antigen presenting cells
AU2003208197A1 (en) Use of soluble fgl2 as an immunosuppressant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 22/2004 UNDER (72, 75) REPLACE "MCKAY, PAUL [GB/GB]; LONDON (GB)." BY "MCKAY, PAUL [GB/GB]; 10 STRILING GROVE, HOUNSLOW, MIDDLESEX, LONDON TW3 1QG (GB)."; "BAROUCH, DAN [US/US]; BROOKLINE, MA (US)." BY "BAROUCH, DAN [US/US] 1 LONGFELLOW PLACE, #3222, BOSTON, MA 02114 (US)."; LETVIN, NORMAN [US/US]; NEWTON, MA (US)." REPLACE "LETVIN, NORMAN [US/US]; 36 BRACKET ROAD, NEWTON, MA 02458 (US)."

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP